Literature DB >> 21788281

Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Pasquapina Ciarmela1, Md Soriful Islam, Fernando M Reis, Peter C Gray, Enrrico Bloise, Felice Petraglia, Wylie Vale, Mario Castellucci.   

Abstract

BACKGROUND: Growth factors are proteins secreted by a number of cell types that are capable of modulating cellular growth, proliferation and cellular differentiation. It is well accepted that uterine cellular events such as proliferation and differentiation are regulated by sex steroids and their actions in target tissues are mediated by local production of growth factors acting through paracrine and/or autocrine mechanisms. Myometrial mass is ultimately modified in pregnancy as well as in tumour conditions such as leiomyoma and leiomyosarcoma. Leiomyomas, also known as fibroids, are benign tumours of the uterus, considered to be one of the most frequent causes of infertility in reproductive years in women.
METHODS: For this review, we searched the database MEDLINE and Google Scholar for articles with content related to growth factors acting on myometrium; the findings are hereby reviewed and discussed.
RESULTS: Different growth factors such as epidermal growth factor (EGF), transforming growth factor-α (TGF-α), heparin-binding EGF (HB-EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF) and TGF-β perform actions in myometrium and in leiomyomas. In addition to these growth factors, activin and myostatin have been recently identified in myometrium and leiomyoma.
CONCLUSIONS: Growth factors play an important role in the mechanisms involved in myometrial patho-physiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788281      PMCID: PMC3191937          DOI: 10.1093/humupd/dmr031

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  187 in total

1.  Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells.

Authors:  P N Rauk; U Surti; J M Roberts; G Michalopoulos
Journal:  Am J Obstet Gynecol       Date:  1995-08       Impact factor: 8.661

Review 2.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

3.  Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta.

Authors:  Xiaoping Luo; Li Ding; Jingxia Xu; Nasser Chegini
Journal:  Endocrinology       Date:  2004-12-16       Impact factor: 4.736

Review 4.  Abnormal gene expression in uterine leiomyomas.

Authors:  J Andersen; R L Barbieri
Journal:  J Soc Gynecol Investig       Date:  1995 Sep-Oct

5.  A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.

Authors:  Jiayin Wang; Noriyuki Ohara; Zhuo Wang; Wei Chen; Akira Morikawa; Hiroko Sasaki; Deborah A DeManno; Kristof Chwalisz; Takeshi Maruo
Journal:  Hum Reprod       Date:  2006-04-13       Impact factor: 6.918

6.  Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway.

Authors:  Judy S Crabtree; Scott A Jelinsky; Heather A Harris; Sung E Choe; Monette M Cotreau; Michelle L Kimberland; Ewa Wilson; Kathryn A Saraf; Wei Liu; Adrienne S McCampbell; Bhuvanesh Dave; Russell R Broaddus; Eugene L Brown; Wenling Kao; Jerauld S Skotnicki; Magid Abou-Gharbia; Richard C Winneker; Cheryl L Walker
Journal:  Cancer Res       Date:  2009-07-21       Impact factor: 12.701

7.  Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial.

Authors:  M Engman; S Granberg; A R W Williams; C X Meng; P G L Lalitkumar; K Gemzell-Danielsson
Journal:  Hum Reprod       Date:  2009-04-23       Impact factor: 6.918

8.  Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3.

Authors:  Doina S Joseph; Minnie Malik; Sahadat Nurudeen; William H Catherino
Journal:  Fertil Steril       Date:  2009-03-27       Impact factor: 7.329

9.  Differential expression of keratinocyte growth factor and its receptor in the human uterus.

Authors:  F Pekonen; T Nyman; E M Rutanen
Journal:  Mol Cell Endocrinol       Date:  1993-09       Impact factor: 4.102

10.  Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues.

Authors:  L T Van der Ven; P J Roholl; T Gloudemans; S C Van Buul-Offers; M J Welters; B A Bladergroen; J A Faber; J S Sussenbach; W Den Otter
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  56 in total

1.  Immunoexpression of Steroid Hormone Receptors and Proliferation Markers in Uterine Leiomyoma and Normal Myometrial Tissues from the Miniature Pig, Sus scrofa.

Authors:  Kristie Mozzachio; Alicia B Moore; Grace E Kissling; Darlene Dixon
Journal:  Toxicol Pathol       Date:  2015-12-20       Impact factor: 1.902

Review 2.  Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy.

Authors:  Mostafa A Borahay; Ayman Al-Hendy; Gokhan S Kilic; Darren Boehning
Journal:  Mol Med       Date:  2015-04-13       Impact factor: 6.354

3.  Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations.

Authors:  James H Segars; Estella C Parrott; Joan D Nagel; Xiaoxiao Catherine Guo; Xiaohua Gao; Linda S Birnbaum; Vivian W Pinn; Darlene Dixon
Journal:  Hum Reprod Update       Date:  2014-01-08       Impact factor: 15.610

4.  Increased urinary cobalt and whole blood concentrations of cadmium and lead in women with uterine leiomyomata: Findings from the ENDO Study.

Authors:  Erica B Johnstone; Germaine M Buck Louis; Patrick J Parsons; Amy J Steuerwald; Christopher D Palmer; Zhen Chen; Liping Sun; Ahmad O Hammoud; Jessie Dorais; C Matthew Peterson
Journal:  Reprod Toxicol       Date:  2014-06-30       Impact factor: 3.143

5.  No REST for fibroids.

Authors:  Bo R Rueda; John S Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-25       Impact factor: 11.205

6.  High expression of calcium channel subtypes in uterine fibroid of patients.

Authors:  Xiaoping Ke; Zhongping Cheng; Xiaoyan Qu; Hong Dai; Wenchao Zhang; Zi-Jiang Chen
Journal:  Int J Clin Exp Med       Date:  2014-05-15

7.  Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function.

Authors:  Md Soriful Islam; William H Catherino; Olga Protic; Milijana Janjusevic; Peter Clarke Gray; Stefano Raffaele Giannubilo; Andrea Ciavattini; Pasquale Lamanna; Andrea Luigi Tranquilli; Felice Petraglia; Mario Castellucci; Pasquapina Ciarmela
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

Review 8.  Recent Advances in Uterine Fibroid Etiology.

Authors:  Michelle M McWilliams; Vargheese M Chennathukuzhi
Journal:  Semin Reprod Med       Date:  2017-03-09       Impact factor: 1.303

9.  Myostatin, a profibrotic factor and the main inhibitor of striated muscle mass, is present in the penile and vascular smooth muscle.

Authors:  I Kovanecz; M Masouminia; R Gelfand; D Vernet; J Rajfer; N F Gonzalez-Cadavid
Journal:  Int J Impot Res       Date:  2017-05-25       Impact factor: 2.896

10.  Non-hormonal mediators of uterine fibroid growth.

Authors:  Esra Cetin; Ayman Al-Hendy; Michał Ciebiera
Journal:  Curr Opin Obstet Gynecol       Date:  2020-10       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.